What is Insilico Medicine?
Insilico Medicine is a pioneering end-to-end artificial intelligence-driven drug discovery company. It leverages advanced machine learning techniques, including deep generative models and reinforcement learning, to accelerate novel target discovery and generate molecular structures with specific desired properties. The company's platform is designed to address critical unmet needs in therapeutic areas such as oncology, fibrosis, infectious diseases, autoimmune disorders, and age-related diseases, positioning it at the forefront of pharmaceutical innovation.
How much funding has Insilico Medicine raised?
Insilico Medicine has raised a total of $509.8M across 7 funding rounds:
Private Equity
$2.8M
Private Equity
$4M
Series A
$6M
Series B
$37M
Series C
$255M
Series D
$95M
Series E
$110M
Private Equity (2016): $2.8M, investors not publicly disclosed
Private Equity (2017): $4M, investors not publicly disclosed
Series A (2018): $6M supported by Pavilion Capital, Juvenescence, Bold Capital Partners, and WuXi AppTec
Series B (2019): $37M featuring BOLD Capital Partners, Pavilion Capital, Lilly Asia Ventures, Qiming Venture Partners, F-Prime Capital, Sinovation Ventures, Baidu Ventures, and Eight Roads
Series C (2021): $255M backed by Pavilion Capital, Warburg Pincus, and Qiming Venture Partners
Series D (2022): $95M with participation from Pavilion Capital, Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners, Prosperity7 Ventures, and BHR Partners
Series E (2025): $110M led by Value Partners SpA
Key Investors in Insilico Medicine
Pavilion Capital
Pavilion Capital Partners is a growth-oriented private equity investor that provides capital and strategic support to fast-growing companies in the United States and Asia, with a particular focus on industries experiencing high growth due to globalization, technology, or demographic trends.
Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm renowned for its expertise in growth investing, supporting investors and management teams in building long-term, sustainable success across diverse market cycles.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that focuses on investing in innovative companies across various sectors, including technology, healthcare, and artificial intelligence, aiming to support entrepreneurs by providing industry resources and strategic guidance.
What's next for Insilico Medicine?
The recent major strategic investment signals Insilico Medicine's transition into a scaling phase, likely focusing on expanding its clinical pipeline and further developing its AI-powered drug discovery infrastructure. This capital infusion will be instrumental in advancing its lead drug candidates through rigorous clinical trials and potentially forging new strategic partnerships. The company's sustained access to significant financing indicates a strong market validation of its technology and its potential to disrupt traditional drug development paradigms, paving the way for future growth and market expansion.
See full Insilico Medicine company page
